Modus Therapeutics Holding AB (publ)
STO: MODTX.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Öhd
- Employees
- 2
- Headquarters
- Stockholm, Sweden
- IPO year
- 2021
- Market cap
- SEK 41.0M
- Website
- https://www.modustx.com
Loading MODTX…
Loading profile data…Frequently asked questions about MODTX
What does Modus Therapeutics Holding AB (publ) (MODTX.ST) do?
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Where does MODTX.ST trade?
Modus Therapeutics Holding AB (publ) (MODTX.ST) trades on the Stockholm Stock Exchange.
What sector is MODTX.ST in?
Modus Therapeutics Holding AB (publ) (MODTX.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Modus Therapeutics Holding AB (publ)?
John Öhd is the chief executive officer of Modus Therapeutics Holding AB (publ) (MODTX.ST).
Where is Modus Therapeutics Holding AB (publ) headquartered?
Modus Therapeutics Holding AB (publ) is headquartered in Sweden.
Does MODTX.ST pay a dividend?
Modus Therapeutics Holding AB (publ) (MODTX.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MODTX.ST go public?
Modus Therapeutics Holding AB (publ) (MODTX.ST) completed its initial public offering in 2021.